SBMU, Pharmaceutical Research Sciences
  • Register
  • Login
International Pharmacy Acta
  • Home
  • Journal Info
    • About
    • Aim and Scope
    • Ownership & Management
    • Indexing
    • Editorial Team
  • New Submission
  • Author Guidelines
    • Guideline
    • Types of articles
    • Templates
    • Publication Fees
  • Policies and Process
    • Publication Policy
    • Peer Review Process
    • Open Access Policy
    • plagiarism
    • Archiving
    • Privacy Statement
    • Copyright Notice
    • Waiver policy
    • Complaints Policy
    • Post- Publication Discussions and Corrections Policy
    • Advertisement and Marketing
  • Issues
    • Current
    • Archives
  • Contact us
Advanced Search
  1. Home
  2. Archives
  3. Vol. 1 No. 1 (2018): Pharmacy Updates 2018 (Congress Proceeding)
  4. Supplementary Issues: Reviews of books, journal, congress, other media Special issues, and Scientific news

Vol. 1 No. 1 (2018)

March 2018

The genoprotective effect of Naringin by mifepristone on human blood lymphocyte

  • Mohboobeh Rahmati
  • Mohammad Shokrzadeh
  • Narges Kargar Darabi
  • Mona Modanloo
  • Marjan Fallah
  • Abbas Mohammadpour

International Pharmacy Acta, Vol. 1 No. 1 (2018), 4 March 2018 , Page 150-151
https://doi.org/10.22037/ipa.v1i1.20497 Published: 2018-03-04

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

Introduction: According to a study conducted by mifepristone, it is a potent anti-progesterone compound that can lead to abortion and abnormalities in the fetus. Therefore, due to the presence of high antioxidant flavonoids, such as Naringin, and the frequency of this compound in the country, we have determined the protective effect of Naringin against cytogenetic damage caused by mifepristone on blood lymphocytes with micronucleus method; a high dose causes abortion and genetic abnormalities.

Methods and Results: With 5-cc heparin syringe, blood samples were collected from 5 healthy and non-smoker volunteers and blood samples were incubated for 1 hour after incubation with 100 μM of toxic dose of mifepristone and various concentrations of Naringin for 24 hours. Then to evaluate the production of micronucleus in binucleated lymphocytes, the slides were prepared and were evaluated by optical microscopy. The mean values were compared using the Spss software and the Anova test (posttest: Tukey). That p <0.05 has been made as meaningful. Incubation of blood samples with mifepristone induces genotoxicity in lymphocytes and the adjacency of cells with Naringin significantly reduces the number of micronucleus (p<0.05). The results of this study have shown a significant role of Naringin as the protective factor against the genotoxicity of mifepristone.

Conclusion: In this study, Naringin was found to be a protective agent against the DNA damage caused by mifepristone, and since Naringin alone has no genetic disorder; it can be used as a protective agent against the toxic effects of mifepristone.

Keywords:
  • Genotoxicity, Mifepristone, Naringin, Human lymphocyte, Micronucleus
  • PDF

How to Cite

Rahmati, M., Shokrzadeh, M., Kargar Darabi, N., Modanloo, M., Fallah, M., & Mohammadpour, A. (2018). The genoprotective effect of Naringin by mifepristone on human blood lymphocyte. International Pharmacy Acta, 1(1), 150–151. https://doi.org/10.22037/ipa.v1i1.20497
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 320 times
  • PDF Downloaded: 177 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Information

  • For Readers
  • For Authors
  • For Librarians

Make a Submission

Make a Submission
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Creative Commons License
This journal (and its contents) is licensed under a  Creative Commons Attribution-NonCommercial 4.0 International License.

 

                                                  Online ISSN: 2645-3266

                                                  Print ISSN: 2645-3258                                                 

Powered by OJSPlus